BioInvent International AB: A Strategic Move in Biotechnology

In a significant development within the biotechnology sector, BioInvent International AB, a Swedish research and development company specializing in health care, has made headlines with a strategic transaction involving its antibody library. On May 27, 2025, BioInvent announced that XOMA Royalty Corporation had acquired the future royalty and milestone rights for mezagitamab (TAK-079) for up to $30 million. This deal marks a pivotal moment for BioInvent, reflecting its ongoing efforts to leverage its innovative human antibody libraries across various applications.

Transaction Details

The transaction, confirmed by multiple sources including Seeking Alpha, GlobeNewswire, and Finviz, involves an initial payment of $20 million at closing, with an additional $10 million contingent upon mezagitamab receiving FDA marketing approval for IgA nephropathy. This strategic acquisition positions XOMA Royalty to receive up to $16.25 million in milestones from Takeda, along with mid-single-digit royalties on future commercial sales of mezagitamab.

Impact on BioInvent

BioInvent, listed on the Swedish Stock Exchange, has seen its stock price fluctuate significantly over the past year, with a 52-week high of 50.8 SEK and a low of 22.7 SEK. As of May 25, 2025, the close price stood at 37.1 SEK. The company’s market capitalization is approximately 2.07 billion SEK, with a price-to-earnings ratio of -4.65, indicating its current financial challenges.

The sale of mezagitamab rights is a strategic move for BioInvent, allowing it to capitalize on its research and development capabilities while navigating its financial landscape. Fredrik Johansson, CEO of Energifonden Sverige, commented on the broader investment opportunities in the energy sector, highlighting the diverse investment landscape beyond biotechnology.

Market Reaction and Speculation

Prior to the public announcement of the deal, there was speculation about the transaction, with BioInvent’s stock experiencing a surge. However, once the news was officially released, the stock price adjusted. Neither BioInvent, the buyer, nor Redeye, the analysis firm that interviewed BioInvent’s CEO, acknowledged any information leaks regarding the deal.

This transaction underscores BioInvent’s commitment to advancing its role in the biotechnology industry through strategic partnerships and licensing agreements. As the company continues to develop and manufacture protein-based drugs, this deal with XOMA Royalty represents a significant step forward in its mission to innovate within the health care sector.

For more information on BioInvent International AB and its ongoing projects, visit their official website at www.bioinvent.com .